Abstract
In a recent study by He et al, the nomogram integrates postoperative serum tumor markers such as carbohydrate antigen 19-9 and carcinoembryonic antigen, thereby improving the accuracy of identifying high-risk patients compared to relying solely on preoperative markers, which has significant implications for customizing adjuvant therapy and potentially improving outcomes for this aggressive form of cancer. However, the study's single-center design and short follow-up period may limit the generalizability of its findings and potentially introduce reporting bias. Future studies could consider additional confounding factors, such as adjuvant chemotherapy and variations in surgical techniques, to improve the model's accuracy. Furthermore, it would be valuable to validate the nomogram in broader, prospective cohorts and explore the inclusion of additional markers like circulating tumor DNA to refine further its predictive power and applicability across diverse patient populations.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have